Physician profile
Robert Drake
NPI 1730153818
$1,941.05
in general payments reported to CMS, 2019-2025
20 companies · $84.99 in 2025
The $84.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $227 · 2023: $150 · 2024: $84.74 · 2025: $84.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $339.59 | 2019-2020 | |
| Abbott Laboratories | $240.73 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $214.96 | 2019-2020 | |
| Pfizer INC. | $184.99 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $182.68 | 2019-2020 | |
| Lilly USA, LLC | $127.67 | 2019 | |
| Amarin Pharma, INC. | $114.76 | 2019-2020 | |
| Amgen INC. | $103.98 | 2019-2020 | |
| Glaxosmithkline, LLC. | $101.93 | 2019-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.20 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $68.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.75 | 2019 | |
| Ironwood Pharmaceuticals, INC | $23.92 | 2019 | |
| Genentech USA, INC. | $23.73 | 2019 | |
| Merck Sharp & Dohme LLC | $21.97 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $18.76 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.59 | 2019 | |
| Astellas Pharma US INC | $12.98 | 2019 | |
| Bardy Diagnostics, INC. | $8.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Drake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.